Cytokinetics Inc
CYTKHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET
58.53+2.35 (4.18%)
2026-11-12 05:25 CET
Market cap
8,153.40 USD m
Revenue, TTM
113.29 USD m
Net income, TTM
-777.89 USD m
Free cash flow, TTM
-588.58 USD m
EPS diluted, TTM
-6.04
P/E
-
Price
CYTK against its 20, 50 and 200-day averages2050200beat
33.7% under the 52-week high of 88.31 on 30 Jun 2026. 52-week low 53.55 on 6 Nov 2026. Last 15 sessions, 21.3% high to low
Volume 1.42× normal · the line is the 50-bar volume average
Profile
CYTK52-week range, 14% of the way up
53.5588.31
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
| Index | RUT |
|---|---|
| Employees | 673 |
| IPO | Apr 29, 2004 |
| Beta | 0.49 |
| ATR, 14d | 2.78 |
| Rel volume | 1.42 |
| Short float | 13.34% |
| Insider own | 3.51% |
| Inst own | 112.86% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | 8.15B |
| Enterprise Value | 8.29B |
| Income | -777.89M |
| Sales | 113.29M |
| Book/sh | -2.31 |
| Cash/sh | 8.13 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 673 |
| IPO | Apr 29, 2004 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | 71.97 |
| P/B | - |
| P/C | 7.20 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | 73.20 |
| Quick Ratio | 3.36 |
| Current Ratio | 3.36 |
| Debt/Eq | - |
| LT Debt/Eq | - |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | -6.04 |
|---|---|
| EPS next Y | -4.32 |
| EPS next Q | -1.41 |
| EPS this Y | 8.64% |
| EPS next Y | 27.77% |
| EPS next 5Y | 34.14% |
| EPS past 3/5Y | -14.71% -27.07% |
| Sales past 3/5Y | -2.36% 9.54% |
| EPS Y/Y TTM | 4.30% |
| Sales Y/Y TTM | 29.90% |
| EPS Q/Q | 46.43% |
| Sales Q/Q | 2356.46% |
| Earnings | Nov 04 AMC |
| EPS/Sales Surpr. | 4.44% 13.55% |
Ownership
| Insider Own | 3.51% |
|---|---|
| Insider Trans | -5.77% |
| Inst Own | 112.86% |
| Inst Trans | 9.82% |
| ROA | -47.70% |
| ROE | - |
| ROIC | -102.95% |
| Gross Margin | 78.92% |
| Oper. Margin | -625.15% |
| Profit Margin | -686.63% |
| SMA20 | -3.71% |
| SMA50 | -9.65% |
| SMA200 | -16.23% |
| Trades | - |
Technical
| Shs Outstand | 139.22M |
|---|---|
| Shs Float | 134.41M |
| Short Float | 13.34% |
| Short Ratio | 9.05 |
| Short Interest | 17.93M |
| 52W High | 88.31 -33.72% |
| 52W Low | 53.55 9.30% |
| Volatility | 6.76% 4.19% |
| ATR (14) | 2.78 |
| RSI (14) | 42.87 |
| Beta | 0.49 |
| Rel Volume | 1.42 |
| Avg Volume | 1.98M |
| Volume | 2,811,777 |
Performance
| Perf Week | -7.97% |
|---|---|
| Perf Month | -5.01% |
| Perf Quarter | -20.31% |
| Perf Half Y | -24.20% |
| Perf YTD | -7.88% |
| Perf Year | -11.98% |
| Perf 3Y | 80.09% |
| Perf 5Y | 48.14% |
| Perf 10Y | 422.59% |
| Recom | 1.22 |
| Target Price | 109.42 |
| Prev Close | 56.18 |
| Price | 58.53 |
| Change % | 4.18% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Jun 29, 2026 | Upgrade | UUBS | Neutral → Buy | $115 | +96.5% |
| May 19, 2026 | Initiated | CCitigroup | Buy | $99 | +69.1% |
| Apr 10, 2026 | Initiated | WWells Fargo | Overweight | $95 | +62.3% |
| Jan 28, 2026 | Resumed | BBarclays | Overweight | $87 | +48.6% |
| Dec 18, 2025 | Upgrade | GGoldman | Neutral → Buy | $95 | +62.3% |
| Jul 30, 2025 | Resumed | RRaymond James | Mkt Perform | ||
| Apr 24, 2025 | Initiated | BBarclays | Overweight | $55 | -6.0% |
| Feb 07, 2025 | Initiated | CCitigroup | Buy | $86 | +46.9% |
| Jan 22, 2025 | Initiated | SStifel | Buy | $80 | +36.7% |
| Nov 08, 2024 | Initiated | RRBC Capital Mkts | Outperform | $80 | +36.7% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| EWTX | Edgewise Therapeutics Inc | 5.21B |
| BBIO | BridgeBio Pharma Inc | 15.49B |
| ALNY | Alnylam Pharmaceuticals Inc | 21.41B |
| BMY | Bristol-Myers Squibb Co | 128.59B |
| IONS | Ionis Pharmaceuticals Inc | 4.72B |
| TNYA | Tenaya Therapeutics Inc | 84.61M |
| ARWR | Arrowhead Pharmaceuticals Inc | 6.97B |
| MLYS | Mineralys Therapeutics Inc | 1.43B |
| MIST | Milestone Pharmaceuticals Inc | 82.44M |
| UTHR | United Therapeutics Corp | 25.37B |
Insider trading
latest 14 of 100| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| B LYNNE PARSHALL | Director | Nov 09 '26 | Proposed Sale | 53.69 | 5,000 | 268,450 | Nov 09 04:35 PM | |
| Malik Fady Ibraham | EVP Research & Development | Nov 03 '26 | Option Exercise | 7.80 | 3,500 | 27,300 | 157,402 | Nov 03 04:38 PM |
| Malik Fady Ibraham | EVP Research & Development | Nov 03 '26 | Sale | 62.93 | 3,500 | 220,255 | 153,902 | Nov 03 04:38 PM |
| Blum Robert I | President & CEO | Nov 02 '26 | Option Exercise | 10.60 | 7,500 | 79,500 | 286,044 | Nov 02 06:18 PM |
| Blum Robert I | President & CEO | Nov 02 '26 | Sale | 62.81 | 7,500 | 471,075 | 278,544 | Nov 02 06:18 PM |
| FADY MALIK | Officer | Oct 20 '26 | Proposed Sale | 62.65 | 16,386 | 1,026,583 | Oct 20 04:25 PM | |
| Malik Fady Ibraham | EVP Research & Development | Oct 20 '26 | Option Exercise | 7.80 | 3,500 | 27,300 | 157,402 | Oct 20 04:21 PM |
| Malik Fady Ibraham | EVP Research & Development | Oct 20 '26 | Sale | 64.01 | 3,500 | 224,035 | 153,902 | Oct 20 04:21 PM |
| Blum Robert I | President & CEO | Oct 12 '26 | Option Exercise | 10.60 | 7,500 | 79,500 | 286,044 | Oct 13 04:00 PM |
| Blum Robert I | President & CEO | Oct 12 '26 | Sale | 62.88 | 7,500 | 471,600 | 278,544 | Oct 13 04:00 PM |
| ROBERT BLUM | Director | Oct 12 '26 | Proposed Sale | 62.91 | 22,500 | 1,415,475 | Oct 13 08:19 AM | |
| Malik Fady Ibraham | EVP Research & Development | Oct 06 '26 | Option Exercise | 7.80 | 3,500 | 27,300 | 157,402 | Oct 06 04:25 PM |
| Malik Fady Ibraham | EVP Research & Development | Oct 06 '26 | Sale | 61.38 | 3,500 | 214,830 | 153,902 | Oct 06 04:25 PM |
| Blum Robert I | President & CEO | Sep 28 '26 | Option Exercise | 10.60 | 7,500 | 79,500 | 286,044 | Sep 28 04:54 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 687.42B |
| IJH | iShares Core S&P Mid-Cap ETF | AUM: 124.48B |
| VB | Vanguard Morningstar Small-Cap ETF | AUM: 79.59B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.38B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.50B |
| VBK | Vanguard Morningstar Small-Cap Growth ETF | AUM: 22.34B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
| TCAF | T. Rowe Price Capital Appreciation Equity ETF | AUM: 7.62B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.10B |
| MDY | State Street SPDR S&P MIDCAP 400 ETF Trust | AUM: 26.22B |
News
latest 14 of 200- Mid-cap biotech catalysts: FDA dates, earnings, and pipeline data to watch (Investing.com)
- Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 (GlobeNewswire)
- FDA Decision Watch: Summits Lung Cancer Drug, Cytokinetics Heart Therapy And Tevas Igalmi In Spotlight This Week (Stocktwits)
- Cytokinetics Beats As MYQORZO Sales Jump 76%, But A Flat Operating Loss And Slumping Shares Keep The Bar High (Earnings Whispers) -12.66%
- Cytokinetics: Q3 Earnings Snapshot (Associated Press)
- Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
- Cytokinetics to Participate in November Investor Conferences (GlobeNewswire)
- Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 (GlobeNewswire)
- Cytokinetics Must Show MyCORSO Launch Can Outrun Summer Slowdown As Stock Slides 25% (Earnings Whispers)
- Cytokinetics to Announce Third Quarter Results on November 4, 2026 (GlobeNewswire)
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Cytokinetics Announces Health Canada Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (GlobeNewswire)
- Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026 (GlobeNewswire)
- Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates The Weeks Biotech Watchlist (Stocktwits)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-11-04 | -1.370 | -1.434 | -1.370 | 47.56 | 41.88 | 21 |
| 2026Q2 | 2026-08-06 | -1.500 | -1.628 | -1.505 | 28.62 | 17.59 | 20 |
| 2026Q1 | 2026-05-05 | -1.670 | -1.652 | -1.671 | 19.36 | 8.52 | 20 |
| 2025Q4 | 2026-02-24 | -1.500 | -1.564 | -1.495 | 17.76 | 6.93 | 16 |
| 2025Q3 | 2025-11-05 | -2.550 | -1.571 | -2.552 | 1.94 | 6.05 | 19 |
| 2025Q2 | 2025-08-07 | -1.120 | -1.430 | -1.125 | 66.77 | 2.11 | 19 |
| 2025Q1 | 2025-05-06 | -1.360 | -1.369 | -1.362 | 1.60 | 3.42 | 21 |
| 2024Q4 | 2025-02-27 | -1.260 | -1.193 | -1.271 | 16.93 | 1.75 | 20 |
| 2024Q3 | 2024-11-06 | -1.360 | -1.235 | -1.364 | 0.46 | 1.21 | 16 |
| 2024Q2 | 2024-08-08 | -1.310 | -1.057 | -1.312 | 0.25 | 7.61 | 16 |
| 2024Q1 | 2024-05-08 | -1.330 | -1.144 | -1.331 | 0.84 | 0.91 | 16 |
| 2023Q4 | 2024-02-27 | -1.380 | -0.959 | -1.382 | 1.67 | 7.62 | 17 |
| 2023Q3 | 2023-11-02 | -1.350 | -0.743 | -1.347 | 0.38 | 20.24 | 15 |
| 2023Q2 | 2023-08-03 | -1.340 | -1.139 | -1.343 | 0.87 | 5.67 | 14 |
| 2023Q1 | 2023-05-04 | -1.380 | -1.199 | -1.380 | 4.61 | 2.08 | 13 |
| 2022Q4 | 2023-03-01 | -1.450 | -1.206 | -1.451 | 1.96 | 7.10 | 15 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2019FY | -2.110 | -2.030 | -2.114 | 26.87 | 29.38 |
| 2020FY | -1.970 | -1.710 | -1.973 | 55.83 | 70.03 |
| 2021FY | -2.800 | -3.262 | -2.800 | 70.43 | 20.72 |
| 2022FY | -4.330 | -4.062 | -4.330 | 94.59 | 99.32 |
| 2023FY | -5.450 | -4.879 | -5.452 | 7.53 | 21.85 |
| 2024FY | -5.260 | -5.185 | -5.265 | 18.47 | 3.20 |
| 2025FY | -6.540 | -6.491 | -6.540 | 88.04 | 76.88 |
| 2026FY | - | -5.975 | - | - | 161.94 |
| 2027FY | - | -4.316 | - | - | 443.1 |
| 2028FY | - | -1.869 | - | - | 921.96 |
| 2029FY | - | 1.055 | - | - | 1,595 |
| 2030FY | - | 4.489 | - | - | 2,417 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q4 | S | 2026-11-10 | 20 | 10 | 3 | 64.28 | 52.98 | 82.45 |
| 2026Q4 | S | 2026-11-05 | 20 | 10 | 4 | 64.28 | 52.98 | 82.45 |
| 2026Q4 | S | 2026-11-04 | 20 | 6 | 0 | 61.97 | 49.84 | 85.96 |
| 2026Q4 | S | 2026-10-29 | 20 | 6 | 0 | 61.97 | 49.84 | 85.96 |
| 2026Q4 | S | 2026-10-28 | 21 | 6 | 0 | 60.72 | 35.71 | 85.96 |
| 2026Q4 | S | 2026-10-26 | 21 | 7 | 0 | 60.72 | 35.71 | 85.96 |
| 2026Q4 | S | 2026-10-21 | 21 | 8 | 0 | 60.72 | 35.71 | 85.96 |
| 2026Q4 | S | 2026-10-19 | 21 | 18 | 2 | 60.72 | 35.71 | 85.96 |
| 2026Q4 | S | 2026-10-16 | 21 | 17 | 3 | 59.95 | 33.84 | 85.96 |
| 2026Q4 | S | 2026-10-14 | 21 | 17 | 3 | 59.87 | 33.84 | 85.96 |
| 2026Q4 | S | 2026-10-13 | 20 | 17 | 3 | 59.78 | 33.84 | 85.96 |
| 2026Q4 | S | 2026-10-07 | 20 | 15 | 3 | 58.88 | 33.84 | 85.96 |
| 2026Q4 | S | 2026-09-09 | 20 | 15 | 3 | 58.34 | 33.84 | 85.24 |
| 2026Q4 | S | 2026-08-31 | 20 | 16 | 3 | 58.34 | 33.84 | 85.24 |
Estimate history
| EPS, annual | -2.59 | -1.953 | -2.114 | -1.973 | -2.8 | -4.33 | -5.452 | -5.265 | -6.536 | -6.038 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -1.364 | -1.271 | -1.362 | -1.125 | -2.552 | -1.495 | -1.671 | -1.505 | -1.367 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Sales, annual | 13.368 | 31.501 | 26.868 | 55.828 | 70.428 | 94.588 | 7.53 | 18.474 | 88.039 | 113.29 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 0.463 | 16.927 | 1.579 | 66.769 | 1.936 | 17.755 | 19.355 | 28.624 | 47.557 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Shares, annual | 53.961 | 54.718 | 59.172 | 71.015 | 84.8 | 94.834 | 101.638 | 118.209 | 122.943 | 139.22 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 117.889 | 118.209 | 119.22 | 119.604 | 122.119 | 122.943 | 124.238 | 138.762 | 139.22 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 113.29 | 88.04 | 18.47 | 7.53 | 94.59 | 70.43 | 55.83 | 26.87 | 31.50 |
| Cost of Goods Sold Incl. D&A | 23.88 | 10.12 | 9.53 | 11.89 | 8.40 | 9.64 | - | - | - |
| Gross Profit | 89.41 | 77.91 | 8.94 | -4.36 | 86.19 | 60.79 | - | - | - |
| Selling, General and Administrative Excl. Other | 797.66 | 690.17 | 545.19 | 491.84 | 410.39 | 247.10 | 147.94 | 124.44 | 119.18 |
| Research and Development | 383.50 | 405.90 | 329.88 | 318.23 | 232.41 | 150.30 | 95.12 | 84.83 | 89.14 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -708.24 | -612.26 | -536.25 | -496.20 | -324.20 | -186.31 | -93.94 | -98.87 | -88.92 |
| Interest Expense | 136.99 | 103.87 | 86.51 | 57.67 | 51.16 | 29.33 | 38.68 | 27.36 | 21.56 |
| Unusual Expense | -15.00 | 117.25 | 18.30 | 0.00 | 24.94 | 0.00 | 0.00 | -0.30 | - |
| Net Income Before Taxes | -777.89 | -784.96 | -589.53 | -526.24 | -388.95 | -215.31 | -127.29 | -121.69 | -106.29 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -777.89 | -784.96 | -589.53 | -526.24 | -388.95 | -215.31 | -127.29 | -121.69 | -106.29 |
| Net Income From Continuing Operations | -777.89 | -784.96 | -589.53 | -526.24 | -388.95 | -215.31 | -127.29 | -121.69 | -106.29 |
| Net Income | -777.89 | -784.96 | -589.53 | -526.24 | -388.95 | -215.31 | -127.29 | -121.69 | -106.29 |
| EPS (Recurring) | -5.67 | -5.85 | -5.15 | -5.45 | -4.14 | -2.80 | -1.97 | -2.12 | -1.95 |
| EPS (Basic, Before Extraordinaries) | -6.04 | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 | -1.95 |
| EPS (Diluted) | -6.04 | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | -2.11 | -1.95 |
| EBITDA | -694.73 | -602.13 | -526.72 | -484.31 | -315.80 | -176.68 | -92.11 | -97.57 | -87.68 |
| Non-Operating Income (Expense) | 52.34 | 48.42 | 51.53 | 27.63 | 11.34 | 0.33 | 5.33 | 4.24 | 4.19 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 131.33 | 112.29 | 97.84 | 72.06 | 47.85 | 26.83 | 17.62 | 10.76 | 9.76 |
| Price To Sales Ratio | 80.89 | 86.68 | 285.13 | 1,070.22 | 43.51 | 49.76 | 24.02 | 22.74 | 10.92 |
| Gross Margin | 78.92 | 88.50 | 48.41 | -57.93 | 91.12 | 86.32 | - | - | - |
| Operating Margin | -625.15 | -695.44 | -2,902.72 | -6,589.71 | -342.75 | -264.54 | -168.27 | -367.97 | -282.26 |
| Net Margin | -686.63 | -891.60 | -3,191.11 | -6,988.63 | -411.21 | -305.72 | -228.00 | -452.93 | -337.41 |
| Shares Outstanding | 139.22 | 122.94 | 118.21 | 101.64 | 94.83 | 84.80 | 71.02 | 59.17 | 54.72 |
| Market Capitalization | 8,153.40 | 8,153.40 | 5,551.38 | 8,186.50 | 4,335.99 | 3,823.39 | 1,470.79 | 626.86 | 345.77 |
Income statement, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 47.56 | 28.62 | 19.36 | 17.75 | 1.94 | 66.77 | 1.58 | 16.93 |
| Cost of Goods Sold Incl. D&A | 5.86 | 9.22 | 5.93 | 2.86 | 2.68 | 2.29 | 2.30 | 2.38 |
| Gross Profit | 41.69 | 19.40 | 13.43 | 14.89 | -0.74 | 64.48 | -0.72 | 14.54 |
| Selling, General and Administrative Excl. Other | 208.78 | 198.57 | 197.04 | 193.26 | 166.01 | 175.99 | 154.91 | 153.58 |
| Research and Development | 95.64 | 94.18 | 92.15 | 101.54 | 96.55 | 110.27 | 97.54 | 91.25 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -167.09 | -179.17 | -183.62 | -178.37 | -166.75 | -111.51 | -155.63 | -139.04 |
| Interest Expense | 38.48 | 34.83 | 33.34 | 30.34 | 26.32 | 24.27 | 22.95 | 22.59 |
| Unusual Expense | 0.40 | -1.30 | 0.10 | -14.20 | 123.35 | 11.60 | -3.50 | 3.40 |
| Net Income Before Taxes | -190.07 | -198.76 | -206.03 | -183.03 | -306.18 | -134.37 | -161.38 | -150.02 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -190.07 | -198.76 | -206.03 | -183.03 | -306.18 | -134.37 | -161.38 | -150.02 |
| Net Income From Continuing Operations | -190.07 | -198.76 | -206.03 | -183.03 | -306.18 | -134.37 | -161.38 | -150.02 |
| Net Income | -190.07 | -198.76 | -206.03 | -183.03 | -306.18 | -134.37 | -161.38 | -150.02 |
| EPS (Recurring) | -1.36 | -1.51 | -1.67 | -1.58 | -1.83 | -1.06 | -1.38 | -1.25 |
| EPS (Basic, Before Extraordinaries) | -1.37 | -1.50 | -1.67 | -1.49 | -2.55 | -1.12 | -1.36 | -1.27 |
| EPS (Diluted) | -1.37 | -1.50 | -1.67 | -1.49 | -2.55 | -1.12 | -1.36 | -1.27 |
| EBITDA | -163.44 | -175.54 | -180.24 | -175.50 | -164.08 | -109.22 | -153.33 | -136.66 |
| Non-Operating Income (Expense) | 15.90 | 13.94 | 11.02 | 11.47 | 10.25 | 13.00 | 13.70 | 15.01 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 34.72 | 35.71 | 30.39 | 30.50 | 30.70 | 27.54 | 23.55 | 26.30 |
| Price To Sales Ratio | 80.89 | 166.28 | 76.78 | 88.36 | 75.61 | 46.03 | 247.81 | 300.65 |
| Gross Margin | 87.67 | 67.78 | 69.36 | 83.89 | -38.38 | 96.58 | -45.66 | 85.92 |
| Operating Margin | -351.34 | -625.95 | -948.69 | -1,004.60 | -8,613.38 | -167.00 | -9,856.30 | -821.41 |
| Net Margin | -399.67 | -694.39 | -1,064.48 | -1,030.87 | -15,814.98 | -201.25 | -10,220.14 | -886.28 |
| Shares Outstanding | 139.22 | 138.76 | 124.24 | 122.94 | 122.12 | 119.60 | 119.22 | 118.21 |
| Market Capitalization | 8,153.40 | 10,600.45 | 8,117.67 | 7,768.72 | 6,576.35 | 3,945.87 | 4,758.94 | 5,551.38 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 885.34 | 1,076.39 | 615.20 | 782.58 | 471.64 | 464.06 | 225.11 | 198.73 | 268.89 |
| Short Term Receivables | 17.76 | 16.65 | 1.28 | 0.15 | 51.82 | 4.42 | 5.16 | 6.79 | 1.11 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 13.88 | 14.90 | 11.57 | 12.46 | 12.21 | 5.74 | 3.48 | 2.16 | 4.29 |
| Total Current Assets | 916.98 | 1,107.94 | 628.05 | 795.19 | 535.67 | 474.22 | 233.75 | 207.67 | 274.30 |
| Net Property, Plant & Equipment | 155.17 | 140.97 | 147.74 | 163.19 | 146.41 | 13.35 | 4.53 | 3.20 | 3.57 |
| Total Investments and Advances | 335.05 | 145.06 | 40.53 | 46.71 | 152.05 | 36.95 | 42.65 | 0.00 | 16.52 |
| Intangible Assets | - | - | - | - | - | - | - | - | 0.00 |
| Other Assets | 17.34 | 7.71 | 8.00 | 9.69 | 7.19 | 9.28 | 8.88 | 0.30 | 0.43 |
| Total Assets | 1,424.54 | 1,401.67 | 824.32 | 1,014.77 | 841.32 | 533.80 | 289.81 | 211.18 | 294.81 |
| Short Term Debt Incl. Current Port. of LT Debt | 60.29 | 30.50 | 27.97 | 12.83 | 14.86 | 2.79 | 4.62 | 2.61 | 0.00 |
| Accounts Payable | 22.34 | 20.37 | 21.51 | 25.61 | 21.09 | 8.05 | 8.16 | 3.76 | 5.25 |
| Other Current Liabilities | 119.82 | 128.81 | 53.20 | 46.18 | 35.91 | 20.36 | 13.25 | 15.82 | 27.19 |
| Total Current Liabilities | 202.45 | 179.67 | 102.68 | 84.62 | 71.86 | 31.20 | 26.02 | 22.19 | 32.44 |
| Long Term Debt | 1,223.95 | 758.18 | 727.80 | 736.51 | 255.07 | 135.71 | 131.45 | 39.81 | 31.78 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 657.76 | 599.19 | 380.16 | 301.55 | 270.53 | 253.51 | 143.28 | 123.24 | 120.75 |
| Total Liabilities | 2,084.16 | 1,537.05 | 1,210.64 | 1,122.67 | 597.46 | 420.42 | 300.75 | 185.24 | 184.97 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -659.62 | -135.37 | -386.32 | -107.90 | 243.86 | 113.38 | -10.94 | 25.93 | 109.84 |
| Total Shareholders Equity | -659.62 | -135.37 | -386.32 | -107.90 | 243.86 | 113.38 | -10.94 | 25.93 | 109.84 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -659.62 | -135.37 | -386.32 | -107.90 | 243.86 | 113.38 | -10.94 | 25.93 | 109.84 |
| Total Liabilities & Stockholders Equity | 1,424.54 | 1,401.67 | 824.32 | 1,014.77 | 841.32 | 533.80 | 289.81 | 211.18 | 294.81 |
| Book Value Per Share | -5.37 | -1.15 | -3.80 | -1.14 | 2.88 | 1.60 | -0.18 | 0.47 | 2.04 |
| Tangible Book Value Per Share | -5.37 | -1.15 | -3.80 | -1.14 | 2.88 | 1.60 | -0.18 | 0.47 | 2.04 |
| Full-Time Employees | 673 | 498 | 423 | 409 | 253 | 184 | 156 | 130 | 137 |
| Price to Book Ratio | -25.37 | -398.64 | -18.31 | -271.24 | 15.85 | 13.02 | -57.40 | 13.33 | 2.99 |
| Return on Assets | -55.55 | -52.97 | -57.23 | -41.91 | -31.32 | -30.91 | -48.58 | -42.01 | -54.97 |
| Return on Equity | - | - | - | -572.15 | -120.54 | -248.50 | -1,622.88 | -156.57 | -125.16 |
| Return on Invested Capital | -139.10 | -94.66 | -154.11 | -61.88 | -43.16 | -51.10 | -100.98 | -161.68 | -90.24 |
| Quick Ratio | 4.53 | 6.17 | 6.12 | 9.40 | 7.45 | 15.20 | 8.98 | 9.36 | 8.45 |
| Current Ratio | 4.53 | 6.17 | 6.12 | 9.40 | 7.45 | 15.20 | 8.98 | 9.36 | 8.45 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -777.89 | -784.96 | -589.53 | -526.24 | -388.95 | -215.31 | -127.29 | -121.69 | -106.29 |
| Depreciation | 13.52 | 10.12 | 9.53 | 11.89 | 8.40 | 9.64 | 1.83 | 1.29 | 1.24 |
| Other Funds (Non Cash) | 222.49 | 300.45 | 148.44 | 96.93 | 105.74 | 54.70 | 45.28 | 29.83 | 26.77 |
| Funds from Operations | -541.88 | -474.38 | -431.55 | -417.42 | -274.81 | -150.98 | -80.17 | -90.57 | -78.28 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -30.09 | -35.63 | 35.66 | 3.09 | -24.70 | 8.46 | 89.12 | -0.34 | -22.94 |
| Cash from Operating Activities | -571.97 | -510.01 | -395.89 | -414.33 | -299.52 | -142.52 | 8.94 | -90.91 | -101.22 |
| Capital Expenditures | -16.61 | -24.81 | -3.91 | -1.42 | -11.34 | -48.87 | -11.05 | -2.62 | -0.89 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Purchase or Sale of Investments | -348.16 | 41.47 | -549.19 | 240.67 | -250.80 | -98.91 | -185.46 | -72.09 | 6.01 |
| Purchase of Investments | -1,331.90 | -1,068.17 | -1,293.42 | -635.21 | -855.39 | -525.04 | -435.82 | -277.88 | -240.22 |
| Sale Or Maturity of Investments | 983.74 | 1,109.65 | 744.23 | 875.88 | 604.59 | 426.14 | 250.36 | 205.79 | 246.23 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -364.77 | 16.67 | -553.10 | 239.25 | -262.13 | -147.78 | -196.51 | -74.71 | 5.13 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 836.55 | 35.98 | 759.86 | 182.69 | 17.54 | 304.84 | 231.97 | 37.61 | 3.23 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 836.55 | 35.98 | 759.86 | 182.69 | 17.54 | 304.84 | 231.97 | 37.61 | 3.23 |
| Proceedsfrom Stock Options | 760.15 | 0.00 | 706.84 | 0.00 | 0.00 | 296.90 | 225.11 | 36.21 | 0.00 |
| Issuance or Reduction of Debt, Net | 159.04 | 490.95 | -9.62 | -0.86 | 332.25 | 0.00 | 0.00 | 122.18 | 9.90 |
| Change in Long Term Debt | 159.04 | 490.95 | -9.62 | -0.86 | 332.25 | 0.00 | 0.00 | 122.18 | 9.90 |
| Issuance of Long Term Debt | 175.00 | 904.46 | 0.00 | 0.00 | 521.18 | 0.00 | 0.00 | 135.57 | 9.90 |
| Reduction of Long Term Debt | -15.96 | -413.51 | -9.62 | -0.86 | -188.93 | 0.00 | 0.00 | -13.39 | 0.00 |
| Net Financing Active Other Cash Flow | -79.46 | -2.47 | 180.37 | 39.48 | 166.37 | 15.14 | 2.15 | 0.00 | 0.00 |
| Other Financing Activities Uses | -4.46 | -2.47 | -19.63 | -10.52 | -9.60 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 916.13 | 524.46 | 930.61 | 221.32 | 516.17 | 319.98 | 234.12 | 159.79 | 13.13 |
| Exchange Rate Effect | -1.45 | -0.71 | 0.21 | -0.02 | - | - | - | - | - |
| Net Change in Cash | -22.05 | 30.40 | -18.17 | 46.22 | -45.48 | 29.68 | 46.55 | -5.82 | -82.95 |
| Free Cash Flow | -588.58 | -534.82 | -399.80 | -415.75 | -310.85 | -191.39 | -2.11 | -93.53 | -102.10 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 1,133.12 | 1,168.79 | 821.66 | 885.34 | 965.65 | 859.75 |
| Short Term Receivables | 33.89 | 24.43 | 6.83 | 17.76 | 1.81 | 8.41 |
| Inventories | 0.81 | 0.38 | 0.15 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 19.34 | 14.88 | 10.82 | 13.88 | 9.89 | 18.39 |
| Total Current Assets | 1,187.15 | 1,208.49 | 839.47 | 916.98 | 977.35 | 886.54 |
| Net Property, Plant & Equipment | 147.69 | 151.81 | 156.98 | 155.17 | 153.58 | 146.34 |
| Total Investments and Advances | 453.63 | 538.32 | 254.72 | 335.05 | 288.82 | 178.20 |
| Other Assets | 36.31 | 25.93 | 22.31 | 17.34 | 16.81 | 14.55 |
| Total Assets | 1,824.78 | 1,924.55 | 1,273.48 | 1,424.54 | 1,436.56 | 1,225.63 |
| Short Term Debt Incl. Current Port. of LT Debt | 195.79 | 48.40 | 65.77 | 60.29 | 37.93 | 33.98 |
| Accounts Payable | 25.96 | 20.51 | 24.71 | 22.34 | 22.08 | 16.23 |
| Other Current Liabilities | 131.66 | 112.52 | 108.71 | 119.82 | 82.13 | 80.85 |
| Total Current Liabilities | 353.42 | 181.43 | 199.19 | 202.45 | 142.14 | 131.06 |
| Long Term Debt | 1,076.77 | 1,222.15 | 1,222.95 | 1,223.95 | 1,158.93 | 824.07 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 715.76 | 694.45 | 677.91 | 657.76 | 656.61 | 639.22 |
| Total Liabilities | 2,145.95 | 2,098.04 | 2,100.05 | 2,084.16 | 1,957.68 | 1,594.36 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -321.17 | -173.49 | -826.57 | -659.62 | -521.12 | -368.72 |
| Total Shareholders Equity | -321.17 | -173.49 | -826.57 | -659.62 | -521.12 | -368.72 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -321.17 | -173.49 | -826.57 | -659.62 | -521.12 | -368.72 |
| Total Liabilities & Stockholders Equity | 1,824.78 | 1,924.55 | 1,273.48 | 1,424.54 | 1,436.56 | 1,225.63 |
| Book Value Per Share | -2.31 | -1.25 | -6.65 | -5.37 | -4.27 | -3.08 |
| Tangible Book Value Per Share | -2.31 | -1.25 | -6.65 | -5.37 | -4.27 | -3.08 |
| Full-Time Employees | - | - | - | 673 | - | - |
| Price to Book Ratio | -25.37 | -12.80 | -12.28 | -14.89 | -17.83 | -14.79 |
| Return on Assets | -47.70 | -56.76 | -65.39 | -55.55 | -52.35 | -44.10 |
| Return on Invested Capital | -25.15 | -18.95 | -51.98 | -32.43 | -48.01 | -29.51 |
| Quick Ratio | 3.36 | 6.66 | 4.21 | 4.53 | 6.88 | 6.76 |
| Current Ratio | 3.36 | 6.66 | 4.21 | 4.53 | 6.88 | 6.76 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Net Income | -190.07 | -198.76 | -206.03 | -183.03 | -306.18 | -134.37 |
| Depreciation | 3.65 | 3.63 | 3.38 | 2.86 | 2.68 | 2.29 |
| Other Funds (Non Cash) | 65.18 | 60.53 | 57.41 | 39.36 | 173.46 | 54.96 |
| Funds from Operations | -121.24 | -134.60 | -145.24 | -140.81 | -130.04 | -77.12 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -2.78 | -25.24 | -0.22 | -1.84 | 22.53 | -51.11 |
| Cash from Operating Activities | -124.02 | -159.84 | -145.46 | -142.65 | -107.50 | -128.24 |
| Capital Expenditures | -0.70 | -4.33 | -5.93 | -5.64 | -9.35 | -4.14 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 68.63 | -502.66 | 151.42 | -65.55 | -61.62 | 57.03 |
| Purchase of Investments | -152.47 | -727.26 | -106.52 | -345.65 | -335.45 | -222.97 |
| Sale Or Maturity of Investments | 221.10 | 224.60 | 257.94 | 280.10 | 273.83 | 279.99 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 67.93 | -507.00 | 145.49 | -71.19 | -70.98 | 52.88 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 12.41 | 798.15 | 11.35 | 14.65 | 6.93 | 6.75 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 12.41 | 798.15 | 11.35 | 14.65 | 6.93 | 6.75 |
| Proceedsfrom Stock Options | -0.00 | 760.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -6.69 | -3.81 | -2.73 | 172.28 | 324.25 | -2.70 |
| Change in Long Term Debt | -6.69 | -3.81 | -2.73 | 172.28 | 324.25 | -2.70 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 175.00 | 729.46 | 0.00 |
| Reduction of Long Term Debt | -6.69 | -3.81 | -2.73 | -2.72 | -405.21 | -2.70 |
| Net Financing Active Other Cash Flow | -0.92 | -1.49 | -0.84 | -76.22 | -0.72 | 74.49 |
| Other Financing Activities Uses | -0.92 | -1.49 | -0.84 | -1.22 | -0.72 | -0.51 |
| Cash from Financing Activities | 4.80 | 792.86 | 7.77 | 110.70 | 330.47 | 78.53 |
| Exchange Rate Effect | -0.56 | -0.59 | -0.48 | 0.19 | 0.05 | -0.68 |
| Net Change in Cash | -51.85 | 125.42 | 7.32 | -102.95 | 152.03 | 2.50 |
| Free Cash Flow | -124.72 | -164.17 | -151.39 | -148.29 | -116.86 | -132.38 |
Revenue breakdown
| Collaboration Revenues | 2024: 3.47M 2025: 8.69M |
|---|---|
| License and Milestone Revenues | 2024: 15.00M 2025: 79.35M |
| United States | 2024: 18.47M 2025: 88.04M |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 13.34% | 17.9M | 134.4M | 1.91M |
| 2026-10-15 | 13.89% | 18.6M | 134.2M | 1.96M |
| 2026-09-30 | 14.41% | 19.3M | 134.2M | 1.92M |
| 2026-09-15 | 13.03% | 17.5M | 134.2M | 2.08M |
| 2026-08-31 | 13.01% | 17.4M | 134.0M | 2.06M |
| 2026-08-14 | 12.23% | 16.3M | 133.5M | 2.07M |
| 2026-07-31 | 12.83% | 15.3M | 119.2M | 2.58M |
| 2026-07-15 | 14.30% | 17.1M | 119.2M | 2.60M |
| 2026-06-30 | 14.74% | 17.6M | 119.2M | 2.55M |
| 2026-06-15 | 12.39% | 14.8M | 119.2M | 2.36M |
| 2026-05-29 | 13.01% | 15.5M | 119.2M | 2.44M |
| 2026-05-15 | 13.81% | 16.5M | 119.2M | 2.46M |
| 2026-04-30 | 13.18% | 15.9M | 120.6M | 1.88M |
| 2026-04-15 | 12.37% | 14.9M | 120.4M | 1.87M |
| 2026-03-31 | 13.17% | 15.8M | 120.4M | 1.93M |
| 2026-03-13 | 13.01% | 15.7M | 120.4M | 1.96M |
| 2026-02-27 | 12.77% | 15.4M | 120.4M | 1.89M |
| 2026-02-13 | 12.38% | 14.8M | 119.4M | 1.89M |
| 2026-01-30 | 11.10% | 13.3M | 119.9M | 1.93M |
| 2026-01-15 | 11.17% | 13.4M | 119.9M | 1.94M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 30.00 | 26.90 | 30.60 | 0.00 | 4.157 | 0.00 | 0.00 | 0.992 | -0.025 | 0.002 |
| call | 35.00 | 21.90 | 25.60 | 0.00 | 3.392 | 0.00 | 0.00 | 0.953 | -0.116 | 0.009 |
| call | 40.00 | 17.00 | 20.60 | 0.00 | 2.725 | 0.00 | 0.00 | 0.940 | -0.110 | 0.011 |
| call | 45.00 | 12.00 | 15.60 | 0.00 | 2.124 | 0.00 | 0.00 | 0.922 | -0.101 | 0.013 |
| call | 47.50 | 9.60 | 13.20 | 0.00 | 1.879 | 0.00 | 0.00 | 0.908 | -0.096 | 0.015 |
| call | 50.00 | 7.20 | 9.60 | 26.10 | 1.162 | 1.00 | 0.00 | 0.884 | -0.096 | 0.018 |
| call | 52.50 | 4.80 | 7.40 | 5.20 | 1.037 | 22.00 | 2.00 | 0.855 | -0.087 | 0.021 |
| call | 55.00 | 3.60 | 5.50 | 4.30 | 0.970 | 70.00 | 28.00 | 0.709 | -0.152 | 0.031 |
| call | 57.50 | 2.20 | 3.40 | 2.55 | 0.785 | 4.00 | 9.00 | 0.582 | -0.178 | 0.036 |
| call | 60.00 | 1.35 | 2.30 | 1.55 | 0.804 | 107 | 138 | 0.451 | -0.171 | 0.036 |
| call | 62.50 | 0.15 | 1.40 | 0.70 | 0.787 | 204 | 95.00 | 0.336 | -0.162 | 0.033 |
| call | 65.00 | 0.50 | 0.75 | 0.41 | 0.756 | 443 | 12.00 | 0.205 | -0.112 | 0.026 |
| call | 67.50 | 0.35 | 0.75 | 0.45 | 0.914 | 62.00 | 3.00 | 0.178 | -0.124 | 0.024 |
| call | 70.00 | 0.20 | 0.30 | 0.25 | 0.819 | 2,886 | 29.00 | 0.091 | -0.070 | 0.015 |
| call | 72.50 | 0.05 | 0.50 | 0.66 | 1.002 | 11.00 | 0.00 | 0.099 | -0.090 | 0.016 |
| call | 75.00 | 0.00 | 0.50 | 0.07 | 1.044 | 580 | 0.00 | 0.075 | -0.077 | 0.013 |
| call | 80.00 | 0.00 | 0.20 | 0.15 | 1.148 | 597 | 8.00 | 0.049 | -0.060 | 0.009 |
| call | 85.00 | 0.00 | 2.15 | 0.48 | 1.320 | 1,103 | 0.00 | 0.044 | -0.063 | 0.008 |
| call | 90.00 | 0.00 | 0.40 | 0.16 | 1.478 | 1,897 | 0.00 | 0.040 | -0.066 | 0.008 |
| call | 95.00 | 0.00 | 2.15 | 0.15 | 1.624 | 5.00 | 0.00 | 0.037 | -0.068 | 0.007 |
| call | 100 | 0.00 | 2.15 | 0.07 | 1.760 | 70.00 | 0.00 | 0.035 | -0.070 | 0.007 |
| call | 105 | 0.00 | 2.15 | 0.01 | 1.887 | 23.00 | 0.00 | 0.033 | -0.071 | 0.007 |
| call | 110 | 0.00 | 2.15 | 0.05 | 1.661 | 24.00 | 0.00 | 0.010 | -0.024 | 0.003 |
| call | 115 | 0.00 | 2.15 | 0.31 | 1.760 | 392 | 0.00 | 0.010 | -0.024 | 0.002 |
| call | 120 | 0.00 | 2.15 | 1.30 | 1.853 | 18.00 | 0.00 | 0.010 | -0.025 | 0.002 |
| call | 125 | 0.00 | 2.15 | 2.00 | 1.942 | 901 | 0.00 | 0.009 | -0.025 | 0.002 |
| put | 30.00 | 0.00 | 2.15 | 1.05 | 1.901 | 1.00 | 0.00 | -0.008 | -0.021 | 0.002 |
| put | 35.00 | 0.00 | 2.15 | 2.30 | 2.207 | 14.00 | 0.00 | -0.047 | -0.112 | 0.009 |
| put | 40.00 | 0.00 | 0.90 | 4.20 | 1.725 | 13.00 | 0.00 | -0.060 | -0.105 | 0.011 |
| put | 45.00 | 0.00 | 2.15 | 2.05 | 1.249 | 20.00 | 0.00 | -0.073 | -0.089 | 0.013 |
| put | 47.50 | 0.00 | 0.45 | 0.10 | 1.081 | 0.00 | 4.00 | -0.092 | -0.091 | 0.015 |
| put | 50.00 | 0.10 | 0.70 | 0.25 | 0.908 | 509 | 4.00 | -0.116 | -0.091 | 0.018 |
| put | 52.50 | 0.05 | 0.80 | 0.40 | 0.702 | 10.00 | 7.00 | -0.145 | -0.081 | 0.021 |
| put | 55.00 | 0.45 | 1.40 | 0.80 | 0.807 | 492 | 34.00 | -0.291 | -0.146 | 0.031 |
| put | 57.50 | 1.30 | 2.80 | 1.80 | 0.922 | 88.00 | 81.00 | -0.418 | -0.171 | 0.036 |
| put | 60.00 | 2.45 | 3.90 | 2.85 | 0.856 | 657 | 93.00 | -0.549 | -0.164 | 0.036 |
| put | 62.50 | 4.10 | 6.60 | 2.90 | 1.166 | 82.00 | 0.00 | -0.664 | -0.155 | 0.033 |
| put | 65.00 | 6.10 | 9.00 | 8.50 | 1.355 | 182 | 0.00 | -0.795 | -0.105 | 0.026 |
| put | 67.50 | 8.40 | 10.90 | 0.00 | 1.361 | 0.00 | 0.00 | -0.822 | -0.116 | 0.024 |
| put | 70.00 | 10.70 | 13.30 | 11.78 | 1.497 | 275 | 1.00 | -0.909 | -0.062 | 0.015 |
| put | 72.50 | 13.10 | 15.70 | 0.00 | 1.617 | 0.00 | 0.00 | -0.918 | -0.065 | 0.014 |
| put | 75.00 | 15.50 | 18.20 | 12.80 | 1.760 | 396 | 0.00 | -0.925 | -0.068 | 0.013 |
| put | 80.00 | 20.50 | 23.40 | 22.43 | 2.097 | 107 | 2.00 | -0.951 | -0.051 | 0.009 |
| put | 85.00 | 25.60 | 28.10 | 20.20 | 2.213 | 53.00 | 0.00 | -0.956 | -0.054 | 0.008 |
| put | 90.00 | 29.50 | 33.40 | 29.00 | 2.550 | 0.00 | 0.00 | -0.960 | -0.056 | 0.008 |
| put | 95.00 | 34.50 | 38.40 | 33.98 | 2.747 | 16.00 | 0.00 | -0.963 | -0.057 | 0.007 |
| put | 100 | 40.20 | 43.10 | 0.00 | 2.796 | 0.00 | 0.00 | -0.965 | -0.059 | 0.007 |
| put | 105 | 44.50 | 48.40 | 0.00 | 3.098 | 0.00 | 0.00 | -0.967 | -0.060 | 0.007 |
| put | 110 | 50.20 | 53.10 | 0.00 | 3.117 | 0.00 | 0.00 | -0.990 | -0.012 | 0.003 |
| put | 115 | 54.50 | 58.40 | 0.00 | 3.405 | 0.00 | 0.00 | -0.990 | -0.011 | 0.002 |
| put | 120 | 60.20 | 63.10 | 0.00 | 3.400 | 0.00 | 0.00 | -0.990 | -0.011 | 0.002 |
| put | 125 | 65.20 | 68.10 | 0.00 | 3.530 | 0.00 | 0.00 | -0.991 | -0.011 | 0.002 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | SCHEDULE 13G | SEC | ||
| 2026-11-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-04 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-04 | 8-K | Current report | 2026-11-04 | SEC |
| 2026-11-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-03 | SEC |
| 2026-11-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-02 | SEC |
| 2026-10-20 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-16 | SEC |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-16 | SEC |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-16 | SEC |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-16 | SEC |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-16 | SEC |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-16 | SEC |
| 2026-10-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-20 | SEC |
| 2026-10-13 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-10-13 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-12 | SEC |
| 2026-10-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-06 | SEC |
| 2026-09-28 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-28 | SEC |
| 2026-09-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-22 | SEC |
| 2026-09-15 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-15 | SEC |
| 2026-09-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-11 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-11 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-11 | SEC |
| 2026-09-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-08 | SEC |
| 2026-09-01 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-01 | SEC |
| 2026-08-31 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-31 | SEC |
| 2026-08-31 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-31 | SEC |
| 2026-08-28 | 8-K | Current report | 2026-08-28 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 691.33K | 2 |
| 2026-10 | 0 | 0 | 910.47K | 3 |
| 2026-09 | 0 | 0 | 8.84M | 8 |
| 2026-08 | 0 | 0 | 2.07M | 4 |
| 2026-07 | 0 | 0 | 4.95M | 8 |
| 2026-06 | 0 | 0 | 3.02M | 7 |
| 2026-05 | 0 | 0 | 7.26M | 9 |
| 2026-04 | 0 | 0 | 3.40M | 7 |
| 2026-03 | 0 | 0 | 7.11M | 13 |
| 2026-02 | 0 | 0 | 983.97K | 2 |
| 2026-01 | 0 | 0 | 1.02M | 2 |
| 2025-12 | 0 | 0 | 7.82M | 9 |
| 2025-11 | 0 | 0 | 943.30K | 4 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 16.15% |
| T. Rowe Price Investment Management, Inc. | 15.04% |
| WELLINGTON MANAGEMENT GROUP LLP | 5.57% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.39% |
| STATE STREET CORP | 5.22% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.92% |
| Avoro Capital Advisors LLC | 4.02% |
| BANK OF AMERICA CORP /DE/ | 3.73% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.71% |
| RTW INVESTMENTS, LP | 2.30% |
Funds
| Fund | % owned |
|---|---|
| iShares Convertible Bond ETF | 12.70% |
| State Street(R) SPDR(R) Bloomberg Convertible Securities ETF | 8.83% |
| Columbia Convertible Securities Fund | 6.83% |
| T. Rowe Price Capital Appreciation Fund | 5.05% |
| Lord Abbett Convertible Fund | 3.81% |
| iShares Core S&P Mid-Cap ETF | 3.73% |
| Putnam Convertible Securities Fund | 3.60% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.47% |
| Fidelity Convertible Securities Fund | 3.44% |
| Fidelity SAI Convertible Arbitrage Fund | 3.15% |
OakChart. CYTK. Cached 15 minutes.